Not Yet Recruiting
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC
NCT07669610
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
- Locations
-
Not specified